Assessing the cardiometabolic effects of tirzepatide in people with type 1 diabetes

Garvan Institute of Medical Research0 个研究点目标入组 24 人开始时间: 2024年2月8日最近更新: 2024年7月29日

适应症

试验速览

暂无简介。

•age 18-60 years
•2 years since diagnosis of type 1 diabetes
•BMI greater than or equal to 30 kg/m2
•Willingness to give written informed consent, participate and comply with the study.

•treatment with a glucagon-like peptide-1 (GLP1) receptor agonist, or a sodium-glucose cotransporter 2 (SGLT2) inhibitor in the last 6 weeks
•treatment with glucocorticoids in the last 6 weeks
•previous bariatric surgery or planned during the trial period
•diabetic ketoacidosis or severe hypoglycaemia in the last 3 months
•eGFR <45 ml/min/1.73m2
•evidence of significant liver disease (known cirrhosis, LFTs > 3x upper limit of normal)
•known gastroparesis
•history of pancreatitis or cholecystitis
•pregnant, breastfeeding or female of childbearing potential not using adequate contraception
•coronary event or stroke in the last 3 months
•history of active proliferative diabetic retinopathy or macular oedema
•cognitive impairment or significant psychiatric illness which impairs ability to understand study requirements

发起方